Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Wow what bad news is next?

<< Previous

Bullboard Posts

Next >>

Comment by woundedkneeon Jun 13, 2022 3:08pm

170 Views

Post# 34752935

RE:RE:Wow what bad news is next?

That's right. Markets are down due to high inflation and a sure recession in the near future. ATE has been trading solely on its cash position as management has failed its shareholders; the markets don't forget all the insider trades leading up to the crash of ATE's share price. And Mugsy, I'll say this. You've got a pair to keep buying this stock, even if it is in dribs and drabs. It may pay off if you're young enough to see lt. Lets hope the new era of Antibe rewards your undying loyalty, even though I think it's futile. gl

<< Previous

Bullboard Posts

Next >>

Changing Europe’s dependency on HREE from China